Marvell Technology Inc vs Revvity Inc — how do they compare? Marvell Technology Inc trades at $274.71 (market cap $246.84B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Marvell Technology Inc is far larger — about 14.5× Revvity Inc's market cap, and Revvity Inc pays the higher dividend (0.18%). Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Revvity Inc for 12 Days on average.
| MRVL | RVTY | |
|---|---|---|
Market Cap | $246.84B | $16.98B |
Volume | 29,003,830 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $316.43 | $157.36 |
52-Week Low | $73.73 | $82.26 |
Typical Hold Time | 42 Days | 12 Days |
Enterprise Value | $248.19B | $19.30B |
Dividend Yield | 0.09% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $275.28, down 3.3% in the last session, but maintains strong technical momentum with bullish moving averages and support at $267. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS expected at $1.1. Revenue growth accelerated to 42% in fiscal 2026, driven by data center products comprising 74% of sales. Analyst consensus remains overwhelmingly bullish with 84% buy ratings and a $327.86 price target, representing 19% upside potential.
Marvell's AI-driven growth story appears compelling with custom chip deals with hyperscalers potentially generating $120 billion in cumulative revenue. However, high valuation multiples (P/E 90.95, P/S 25.77) and recent net losses (-$885M in 2025) present risks. The stock's 210% YTD gain suggests much optimism is priced in, requiring continued execution on the $18 billion fiscal 2028 revenue guidance to justify current levels.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →